Vilobelimab(IFX-1)——一种新型抗C5a单克隆抗体——在早期严重脓毒症或脓毒性休克患者中的疗效与安全性:一项随机、安慰剂对照、双盲、多中心IIa期试验(SCIENS研究)
该多中心、随机、安慰剂对照、双盲IIa期试验在德国11个ICU纳入72例早期严重脓毒症或脓毒性休克成人患者,按2:1随机分配至3个剂量队列接受静脉Vilobelimab或安慰剂:2×2 mg/kg(0和12小时)、2×4 mg/kg(0和24小时)、3×4 mg/kg(0、24和72小时)。共同主要终点为药效学(C5a浓度)、药代动力学(Vilobelimab浓度)和安全性。结果显示Vilobelimab剂量依赖性降低C5a(与基线比P<0.001),给药越频繁C5a下降持续时间越长,50%溶血补体测定的膜攻击复合物裂解能力未受影响;各剂量队列安全性相似,无Vilobelimab特异性不良事件,研究者认为Vilobelimab组治疗中出现的不良事件相关者少于安慰剂组。剂量队列2和3的无ICU天数和无呼吸机天数最高;组间死亡率、无血管加压药天数或无肾脏替代治疗天数无差异。作者认为需进一步研究脓毒症中的C5a抑制。
要点
- 在72例早期严重脓毒症或脓毒性休克成人中,Vilobelimab静脉给药后C5a较基线剂量依赖性下降(P<0.001),给药越频繁C5a下降持续时间越长。
- Vilobelimab不阻断膜攻击复合物形成:50%溶血补体测定的膜攻击复合物裂解能力未受影响。
- 各剂量队列安全性相似,无Vilobelimab特异性不良事件;研究者认为Vilobelimab组治疗中出现的不良事件相关者少于安慰剂组。
- 剂量队列2(2×4 mg/kg,0和24小时)和队列3(3×4 mg/kg,0、24和72小时)的无ICU天数和无呼吸机天数最高。
- 组间死亡率、无血管加压药天数或无肾脏替代治疗天数无差异;作者认为需进一步研究脓毒症中的C5a抑制。
适用人群与场景
- 德国11个多学科ICU的成人患者,患有严重脓毒症或脓毒性休克,且感染相关器官功能障碍为早期起病。
处置流程与药物剂量
- 按2:1随机分配至三个序贯剂量队列接受静脉Vilobelimab或安慰剂:2×2 mg/kg(0和12小时)、2×4 mg/kg(0和24小时)、3×4 mg/kg(0、24和72小时)。
研究设计与关键结果
- 多中心、随机、安慰剂对照、双盲IIa期试验,在德国11个ICU纳入72例患者(每个Vilobelimab剂量队列16例,每个安慰剂剂量队列8例)。
- Vilobelimab给药后C5a较基线剂量依赖性下降(P<0.001);给药越频繁C5a下降持续时间越长;50%溶血补体测定的膜攻击复合物裂解能力未受影响。
- Vilobelimab耐受良好,各剂量队列安全性结果相似;无Vilobelimab特异性不良事件;研究者认为Vilobelimab组治疗中出现的不良事件相关者少于安慰剂组。
- 剂量队列2和3的无ICU天数和无呼吸机天数最高;组间死亡率、无血管加压药天数或无肾脏替代治疗天数无差异。
证据类型、等级与局限
- 证据类型:随机、安慰剂对照、双盲、多中心IIa期试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐;作者认为数据支持进一步研究脓毒症中的C5a抑制。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Anaphylatoxin C5a, a proinflammatory complement split product, plays a central role in mediating organ dysfunction.
OBJECTIVES: This phase II clinical trial was conducted to study safety, tolerability, pharmacokinetics, and pharmacodynamics of vilobelimab, a recombinant monoclonal antibody against C5a, in patients with severe sepsis or septic shock.
DESIGN: Multicenter, randomized, and placebo-controlled study.
SETTING AND PARTICIPANTS: Eleven multidisciplinary ICUs across Germany. Adult patients with severe sepsis or septic shock and with early onset of infection-associated organ dysfunction.
MAIN OUTCOMES AND MEASURES: Patients were randomly assigned in a ratio of 2:1 to three subsequent dosing cohorts for IV vilobelimab or placebo receiving either 2 × 2 mg/kg (0 and 12 hr), 2 × 4 mg/kg (0 and 24 hr), and 3 × 4 mg/kg (0, 24, and 72 hr). Co-primary endpoints were pharmacodynamics (assessed by C5a concentrations), pharmacokinetics (assessed by vilobelimab concentrations), and safety of vilobelimab. Preliminary efficacy was evaluated by secondary objectives.
RESULTS: Seventy-two patients were randomized (16 patients for each vilobelimab dosing cohort and eight patients for each placebo dosing cohort). Vilobelimab application was associated with dosing dependent decrease in C5a compared with baseline (p < 0.001). Duration of C5a decrease increased with more frequent dosing. Membrane attack complex lysis capacity measured by 50% hemolytic complement was not affected. Vilobelimab was well tolerated with similar safety findings in all dose cohorts. No vilobelimab-specific adverse events emerged. For vilobelimab-treated patients, investigators attributed less treatment-emergent adverse events as related compared with placebo. Dosing cohorts 2 and 3 had the highest ICU-free and ventilator-free days. There was no difference in mortality, vasopressor-free days, or renal replacement therapy-free days between the groups.
CONCLUSIONS AND RELEVANCE: Administration of vilobelimab in patients with severe sepsis and septic shock selectively neutralizes C5a in a dose-dependent manner without blocking formation of the membrane attack complex and without resulting in detected safety issues. The data warrant further investigation of C5a inhibition in sepsis.
参考来源
- Bauer M, Weyland A, Marx G, et al. Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study). Crit Care Explor. 2021. PMID: 34806021. doi:10.1097/CCE.0000000000000577
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。